Lupin trades with traction on the BSE

14 Mar 2014 Evaluate

Lupin is currently trading at Rs. 954.45, up by 4.35 points or 0.46% from its previous closing of Rs. 950.10 on the BSE.

The scrip opened at Rs. 950.10 and has touched a high and low of Rs. 958.00 and Rs. 942.00 respectively. So far 13959 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1003.00 on 03-Mar-2014 and a 52 week low of Rs. 595.05 on 14-Mar-2013.

Last one week high and low of the scrip stood at Rs. 992.65 and Rs. 945.00 respectively. The current market cap of the company is Rs. 42817.94 crore.

The promoters holding in the company stood at 46.76% while Institutions and Non-Institutions held 43.22% and 10.02% respectively.

Lupin has received final approval for its Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Aqua Pharmaceuticals' Monodox Capsules 50 mg, 75 mg, and 100 mg.

The company’s Doxycycline Capsules 50mg, 75mg and 100mg are the AB-rated generic equivalents of Aqua Pharmaceuticals, LLC’s Monodox® Capsules 50mg, 75mg and 100mg and are indicated in the treatment of infections caused by various micro-organisms and as an adjunctive therapy in severe acne.

The company has also received final approval from the FDA for its Ciprofloxacin for Oral Suspension, 5 g/100 ml (250 mg/5 ml) and 10 g/100 ml (500 mg/5 ml) to market a generic version of Bayer HealthCare Pharmaceuticals, Inc.’s (Bayer) Cipro for Oral Suspension 5 g/100 ml and 10 g/100 ml.

The company’s Ciprofloxacin Oral Suspension, 5 g/100 ml (250 mg/5 ml) and 10 g/100 ml (500 mg/5 ml) is the generic equivalent of Bayer’s Cipro Oral Suspension 5 g/100 ml (250 mg/5 ml) and 10 g/100 ml (500 mg/5 ml) and indicated for the treatment of infections caused by susceptible isolates of the designated micro-organisms in various conditions and patient populations.

Lupin is the first applicant to file an ANDA for Cipro Oral Suspension 250 mg/ml & 500 mg/ml and as such is entitled to 180 days of marketing exclusivity. Lupin Pharmaceuticals Inc. (LPI), the company’s US subsidiary would commence marketing the products shortly. Monodox Capsules had annual US sales of $180.6 million, whereas Cipro Oral Suspension had annual US sales of $8.6 million.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Lupin Share Price

2195.00 18.20 (0.84%)
14-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1701.35
Dr. Reddys Lab 1191.95
Cipla 1434.60
Zydus Lifesciences 884.50
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×